期刊文献+

IFN-λ对人食管癌细胞增殖的抑制作用及机制 被引量:3

Anti-proliferative activity induced by interferon-lambda in human esophageal carcinoma cells and its mechanism
下载PDF
导出
摘要 目的探讨干扰素lambda(IFN-λ)对6种人食管癌细胞株生长增殖的影响并分析其作用机制。方法采用RT-PCR法检测6种食管癌细胞株IFN-λ受体表达。采用IFN-λ食管癌细胞株干预食管癌细胞株,MTT法检测细胞增殖抑制率;胎盘蓝染色后计数活细胞数;流式细胞术分析各细胞周期分布。结果 6种人食管癌细胞均表达IFN-λ受体;IFN-λ对各食管癌细胞生长均有不同程度的抑制作用;在TE11,YES5、T.Tn细胞株中,IFN-λ作用后72 h可见TE11、YES5、T.Tn活细胞数明显减少;TE11细胞的G1期升高;YES5、T.Tn细胞的Sub-G1期明显升高。结论 IFN-λ体外可抑制食管癌细胞增殖,其机制为诱导细胞凋亡并将细胞阻滞于G1期。 Objective To investigate the growth inhibition of IFN-lambda(IFN-λ) on 6 human esophageal carcinoma cells and analyze the mechanism.Methods The expression of IFN-λ receptors was examined with RT-PCR in 6 human esophageal carcinoma cells.The esophageal carcinoma cells were treated with IFN-λ,then the cell proliferation was evaluated with MTT assay.The kinetics of cell growth was examined with the trypan blue dye exclusion test.The distributions of cell cycle were analyzed with flow cytometer.Results Six esophageal carcinoma cells all expressed IFN-λ receptors.IFN-λ mediated the growth inhibition with the differential sensitivity.In TE11,YES5 and T.Tn cells,viable cell numbers after IFN-λ treatment reduced significantly.IFN-λ enhanced the G1 phase in TE11 cells and sub-G1 phase in YES5 and T.Tn cells.Conclusion IFN-λ can inhibit the growth of esophageal carcinoma cells in vitro through G1 phase arrest or apoptosis.
出处 《山东医药》 CAS 北大核心 2011年第39期6-8,共3页 Shandong Medical Journal
基金 国家自然基金资助项目(81000913 30801356) 河北省国际科技合作计划项目(10396101D) 河北省科学研究与发展计划项目(06276102D-04)
关键词 干扰素lambda 抗增殖 细胞周期阻滞 细胞凋亡 IFN-lambda anti-proliferative activity cell cycle arrest apoptosis
  • 相关文献

参考文献6

  • 1Kotenko SV, Gallagher G, Baurin VV, et al. IFN-ys mediate antiviral protection through a distinct class II eytokine receptor complex [J]. Nat Immunol, 2003,4( 1 ) :69-77.
  • 2Sheppard P, Kindsvogel W, Xu W, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R[ J]. Nat Immunol, 2003,4( 1 ) : 63 -68.
  • 3Brand S, Beigel F, Olszak T, et al. IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression[ J]. Am J Physiol Gastrointest Liver Physiol, 2005,289 ( 5 ) : G960-G968.
  • 4Zitzmann K, Brand S, Baehs S, et al. Novel intefferon-lambdas induce antiproliferative effects in neuroendocrine tumor cells [ J ]. Biothem Biophys Res Commun, 2006,344(4) :1334-1341.
  • 5Wong LH, Krauer KG, Hatzinisiriou I, et al. Interferon resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3c [ J ]. J Biol Chem, 1997,272 (45) : 28779-28785.
  • 6Caraglia M, Leardi A, Corradino S, et al. alpha-interferon potentiates epidermal growth factor receptor-mediated effects on human epidermoid carcinoma KB cells[ J ]. Int J Cancer, 1995,61 (3) :342- 347.

同被引文献35

  • 1任力强,杨晓光,王秀琴,吴.RA538基因功能片段的克隆和对HL-60细胞的作用[J].中华血液学杂志,1995,16(5):229-231. 被引量:2
  • 2Jemal A, Bray F, Center MM, et al. Global cancer statistics [ J ]. CA Cancer J Clin, 2011,61 ( 2 ) : 69 - 90.
  • 3Donnelly RP, Kotenko SV. Interferon-lambda : a new addition to an old family [ J ]. J Interferon Cytokine Res. 2010,30 ( 8 ) :555 - 564.
  • 4Li Q,Kawamura K,Ma G,et al. Interferon-lambda induces G1 phase arrest or apoptosis in oesophageal carcinoma cells and produces an- ti-tumour effects in combination with anti-cancer agents [ J ]. Eur J Cancer, 2010,46( 1 ) : 180 - 190.
  • 5Li Q, Kawamura K, Okamoto S, et al. Adenoviruses-mediated trans- duction of human oesophageal carcinoma cells with the interferon-λ genes produced anti-tumour effects [ J ]. Br J Cancer, 2011,105 (9) :1302 -1312.
  • 6Raulet DH, Gasser S, Gowen BG, et al. Regulation of ligands for the NKG2D activating receptor[ J]. Annu Rev Immunol, 2013,31:413 -441.
  • 7Jiang Y,Kimchi E, Ajani JA. Localized squamous cell carcinoma of the esophagus: bimodality or trimodality approach? [ J]. Future Oncol, 2009,5(2) :157 - 161.
  • 8Rodriguez CP, Adelstein D J, Rice TW, et al. A phase Ⅱ study of perioperative concurrent chemotherapy, gefitinib, and hyperfraction- ated radiation followed by maintenance gefitiuib in locoregionally advanced esophagus and gastroesophageal junction cancer [ J ]. J Thorac Oncol, 2010,5(2) :229 -235.
  • 9Li G, Hu W,Wang J, et al. Phase Ⅱ study of concurrent chemora- diation in combination with erlotinib for locally advanced esophage- al carcinoma[J]. Int J Radiat Oncol Biol Phys, 2010,78(5) :1407 -1412.
  • 10Wainberg ZA, Lin LS, DiCarlo B, et al. Phase Ⅱ trial of modified FOLFOX6 and erlotinih in patients with metastatic or advanced ad- of the oesophagus and gastro-oesophageal junction [J]. Br J Cancer, 2011,105(6) :760 -765.

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部